Ivonescimab in Treatment-Resistant EGFR-Mutant Lung Cancer

⚠️ Why Does It Matter?

EGFR-mutant non-small-cell lung cancer (NSCLC)has limited effective, durable options after third-generation TKIs. The PD-1/VEGF bispecific antibody known as ivonescimab, with chemotherapy, delays progression (PFS) and shows promising signals in patients with brain metastases .

Developer: Discovered and developed by the Chinese biotechnology company Akeso Inc. . International collaboration: US-based Summit Therapeutics was licensed development and marketing rights in regions including North America, Europe, and Japan.

Approval status: Akeso's first marketed bispecific PD-1/VEGF antibody, ivonescimab, was approved in 2024 by China's NMPA for EGFR-mutant NSCLC. It is not yet approved elsewhere, including by the FDA or EMA. However, its potential benefit earned FDA Fast Track designation.

With its mechanism and clinical results, ivonescimab has important NSCLC potential and may find a place particularly after TKIs once global approvals are completed.

🧪 Study Design (HARMONi, Phase 3)

• Population: 438 advanced/metastatic EGFR-mutant NSCLC patients
• Randomization (1:1): Ivonescimab (20 mg/kg Q3W) + carboplatin/pemetrexed (4 cycles, then pemetrexed ± ivonescimab maintenance) vs Placebo + carboplatin/pemetrexed
• Stratification: Brain metastasis status; region (Asia vs NA/EU)
• Primary endpoints: PFS (IRRC), OS
• Secondary endpoints: ORR, DoR, safety/tolerability

📊 Main Findings

⚠️ Safety (TRAEs)

• Any grade: 95% vs 93%
• Grade ≥3: 50% vs 42%
• Grade ≥3 VEGF-related: 7.3% vs 3.2%
• Grade ≥3 irAEs: 9.6% vs 6.0%
• <1% serious bleeding; no new safety signals

🔍 Clinical Commentary and Impact

• A 48% progression-risk reduction in PFS (HR 0.52) is clinically meaningful and consistent.
• OS is borderlineoverall; longer Western follow-up shows a nominal significance trend.
• In patients with brain metastases, clear intracranial benefit may be valuable in real-world practice.
• Safety remains manageable with expected VEGF and immune-related toxicities under appropriate management.

Underlying message: Unlike previous negative PD-1 + chemotherapy trials (KEYNOTE-789, CheckMate-722), these results suggest dual PD-1 + VEGF targeting could become a new second-line standard candidate.